Clinical Trial

Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease

Completed
View on ClinicalTrials.gov →
Summary
A multicenter retrospective study evaluating the effectiveness and safety of ustekinumab combined with low-dose upadacitinib in patients with refractory Crohn's disease.
Trial Details
NCT Number NCT07697547
Lead Sponsor Shanghai 10th People's Hospital
Collaborators: The First Affiliated Hospital of Anhui Medical University, Second Affiliated Hospital of Zhengzhou University
Conditions Inflammatory Bowel Disease (IBD), Crohn's Disease
Enrollment 84 participants
Start Date 2023-07-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13